Design, prototype development and testing of an antibody-drug conjugate using a novel colchicine derivative
Parole chiave ANTIBODY-DRUG CONJUGATION, BLADDER CANCER
Riferimenti JACEK ADAM TUSZYNSKI
Riferimenti esterni Prof. Afsaneh Lavasanifar, Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Canada
Gruppi di ricerca 28- biomedica
Descrizione This proposal aims to create new single chain and/or single domain nano-particles involving antibody-drug conjugation to optimize both selectivity and specificity for molecular targets in metastatic bladder cancer. The payload for targeted delivery will involve our newly designed anti-mitotic compound CCI-001, which is a colchicine derivative with high potency against bladder cancer cells. In collaboration with Prof. A. Lavasanifar we will design, synthesize and test a novel antibody-drug conjugate for its intended use in clinical applications as an efficacious chemotherapy agent.
Conoscenze richieste drug formulation, simple chemical synthesis, some computational drug design
Note The candidate will spend a period of 3-4 months in Canada in the lab of Prof. Lavasanifar.
Scadenza validita proposta 01/11/2020 PROPONI LA TUA CANDIDATURA